Mundipharma
Mundipharma is a privately held pharmaceutical group operating through independent associated companies in 40+ countries, developing and commercialising branded prescription medicines in pain, respiratory, oncology, and infectious diseases, anchored by OxyContin, Targin, Flutiform, and the late-stage antifungal REZZAYO.
- Company typePrivate
- Founded1992
- HeadquartersCambridge, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mundipharma does
Mundipharma is a privately held, Cambridge, UK-headquartered pharmaceutical group that operates as a federation of independently associated national companies across more than 40 countries, employing between 1,001 and 5,000 people globally. The group develops, manufactures, and commercialises prescription medicines across four core therapeutic areas: pain management (anchored by the OxyContin, OxyNorm, MST Continus, and Targin franchises), respiratory disease (Flutiform and related inhaled combination products), oncology, and infectious diseases (notably REZZAYO/rezafungin for candidemia and invasive candidiasis).
The company's revenue model is built on branded specialty pharmaceuticals sold through prescriber, hospital, and retail pharmacy channels, supplemented by geographic licensing and partnership arrangements — most recently a 2026 US commercialisation agreement with CorMedix for REZZAYO. Its underlying technology base is predominantly small-molecule formulation and inhalation-device engineering, extended through the 2018 acquisition of Cinfa Biotech into biosimilars. Late-stage R&D is concentrated on REZZAYO, with Phase III ReSPECT data reported in April 2026 and FDA/EMA submissions planned for 2H 2026 and Q3 2026 respectively, targeting a US market opportunity described as greater than $2 billion.
Operationally, Mundipharma has been actively reshaping its portfolio: it divested its Consumer Health business to iNova Pharmaceuticals in January 2024 to focus on prescription specialty franchises, and continues to operate within a governance framework that includes board-level ESG oversight and a published Modern Slavery Statement. The group's historical association with the Sackler family remains a defining reputational context given the OxyContin franchise.
Mundipharma firmographics
Firmographics- Name
- Mundipharma
- Legal name
- Mundipharma International Limited
- Website
- https://mundipharma.com
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Mundipharma is a privately held pharmaceutical group operating through independent associated companies in 40+ countries, developing and commercialising branded prescription medicines in pain, respiratory, oncology, and infectious diseases, anchored by OxyContin, Targin, Flutiform, and the late-stage antifungal REZZAYO.
- Ownership category
- akta.pro rank
Mundipharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Specialty Pharmaceutical Distributors (HLAIAJAB), Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)
Keywords
Where Mundipharma is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices33 records
Markets served
Mundipharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Others
Revenue model
- Prescription Pharmaceutical Products: Mundipharma generates revenue through the development, manufacture, and sale of prescription pharmaceutical products across therapeutic areas including pain management, respiratory, oncology, and infectious diseases. The company operates through a global network of independent associated companies.
- DefenCath: CorMedix reported record 2025 net sales of approximately $260 million driven by DefenCath's TDAPA reimbursement. CorMedix is Mundipharma's US licensee for REZZAYO.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Mundipharma product offering
Product offeringCore offering
Mundipharma develops, manufactures, and commercializes prescription pharmaceutical products across four core therapeutic areas: pain management (opioid and non-opioid analgesics such as oxycodone and morphine formulations), respiratory conditions (asthma/COPD inhalers), oncology (treatments and supportive care), and infectious diseases (antifungal prophylaxis including REZZAYO). The company operates through a network of independent associated companies distributing products in 40+ countries.
Product overview
Mundipharma is a global pharmaceutical company with a diversified portfolio of prescription medicines and consumer health products. The company operates as a network of independent associated companies and focuses on specialty healthcare solutions. Their therapeutic areas include pain management (opioid analgesics such as OxyContin, OxyNorm, MST Continus, Zytram, Targin), respiratory treatments (Flutiform for inhalation), oncology (Zevalin, Pelmeg), and infectious diseases (REZZAYO antifungal). The portfolio comprises both proprietary developed products and licensed brands, with products available across multiple international markets through their global office network spanning over 40 countries.
Differentiator
Problem solved
Functional benefit
Brands
- REZZAYO: Antifungal medication (rezafungin) for invasive fungal infections
- Mundipharma Pride
Products and services
- REZZAYO (rezafungin) Antifungal medication for the prophylaxis and treatment of invasive fungal diseases, including for patients undergoing allogeneic hematopoietic stem cell transplantation. Co-developed with CorMedix.
- Flutiform (fluticasone propionate/formoterol fumarate) Pressurized metered-dose inhaler for the management of asthma and COPD, available in 50/5µg, 125/5µg, and 250/10µg dosage strengths. Licensed from Jagotec AG.
- MST Continus (morphine sulfate) Prolonged-release morphine sulfate tablets for pain management, available in 5mg, 10mg, 15mg, 30mg, 60mg, 100mg, and 200mg dosages.
- OxyContin (oxycodone hydrochloride) Prolonged-release oxycodone tablets for chronic pain management, available in 5mg, 10mg, 20mg, 40mg, and 80mg dosages.
- OxyNorm (oxycodone hydrochloride) Injectable oxycodone solution and infusion for acute pain management, available as 10mg/ml solution in 1ml and 2ml ampoules.
- Zytram (tramadol hydrochloride) Prolonged-release tramadol tablets for pain management, available in 150mg, 200mg, 300mg, and 400mg dosages.
- Zytram BID (tramadol hydrochloride) Prolonged-release tramadol tablets for pain management, available in 75mg twice-daily dosage.
- TARGIN (oxycodone/naloxone) Combination prolonged-release oxycodone/naloxone tablets used in pain management.
- BUTRANS (buprenorphine transdermal) Registered transdermal pain management product of the Mundipharma network.
- ZEVALIN Registered oncology product in the Mundipharma network used in cancer treatment.
- PELMEG (pegfilgrastim) Registered oncology supportive-care biosimilar in the Mundipharma network.
Quantifiable outcome
- 60.7% fungal-free survival at Day 90 for REZZAYO versus 59.0% for standard regimen in Phase III ReSPECT trial
- +1 more outcomes
Companies that use Mundipharma
Customer profileSegments5 records
Ideal customer profiles1 record
Mundipharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Mundipharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CorMedix TherapeuticscoreMundipharma and CorMedix partnered on the development and commercialization of REZZAYO (rezafungin) for prophylaxis of invasive fungal diseases. The Phase III ReSPECT trial met its primary endpoint demonstrating non-inferiority with 60.7% fungal-free survival at Day 90. The companies plan to submit for FDA approval in 2H26 and EMA approval in Q3 2026. The US market opportunity is estimated to exceed $2 billion.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Mundipharma competitors and assessment
Company assessmentDirect peers
- Mallinckrodt: Specialty pharmaceutical company with branded specialty franchises including pain management. Operates across multiple therapeutic areas with a similar specialty-pharma profile to Mundipharma, including legacy opioid exposure.
- Purdue Pharma: Pharmaceutical company historically anchored by OxyContin and other opioid analgesics, sharing therapeutic focus and brand portfolio overlap with Mundipharma's pain franchise. Closely comparable on opioid product positioning.
- Grünenthal: Privately-held German specialty pharmaceutical company with a strong pain management franchise (including branded opioid and non-opioid analgesics) and global commercial operations. Highly comparable to Mundipharma in therapeutic focus and privately-held, specialty-pain-led business model.
- Endo International: Specialty pharmaceutical company with significant pain management portfolio (including opioid analgesics) and branded specialty franchises. Comparable to Mundipharma across pain management focus and specialty pharma positioning, though Endo has faced opioid-related litigation.
Emerging players
- Cidara Therapeutics: Clinical-stage biotechnology company developing antifungal therapies including rezafungin-related programs. Directly comparable to REZZAYO's therapeutic area and competitive positioning in the antifungal space.
Regional players
- Hikma Pharmaceuticals: Specialty pharmaceutical company with strong presence in Middle East, North Africa, and other regional markets, plus specialty injectable and branded portfolio. Comparable to Mundipharma on specialty pharma positioning with regional market overlap.
Broad incumbents
- Stada Arzneimittel: European-headquartered specialty pharmaceutical company with consumer health and specialty care portfolio across multiple therapeutic areas. Comparable as a European specialty pharma peer with similar multi-country distribution model.
- Viatris: Global pharmaceutical company with broad specialty and generics portfolio across multiple therapeutic areas. Comparable to Mundipharma's diversified specialty/generic-style positioning across pain, respiratory, and other areas.
- Astellas Pharma: Global pharmaceutical company with established antifungal franchise and specialty care portfolio. Comparable as a broader incumbent in antifungal/anti-infective therapeutics where REZZAYO competes, and a meaningful peer in specialty pharma.
- GSK (GlaxoSmithKline): Global pharmaceutical major with established respiratory franchise (including inhaler products competing with Flutiform) and broad specialty portfolio. Comparable as a broad incumbent in respiratory therapeutics where Mundipharma operates.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Mundipharma social profiles
Digital presenceMundipharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mundipharma leadership team
Management profileNumber of profiles
Profiles9 records
Mundipharma subsidiaries and ownership
Company hierarchySubsidiaries8 records
Mundipharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mundipharma M&A and investment
M&A and investmentM&A2 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mundipharma
What does Mundipharma do?
Mundipharma develops, manufactures, and commercializes prescription pharmaceutical products across four core therapeutic areas: pain management (opioid and non-opioid analgesics such as oxycodone and morphine formulations), respiratory conditions (asthma/COPD inhalers), oncology (treatments and supportive care), and infectious diseases (antifungal prophylaxis including REZZAYO). The company operates through a network of independent associated companies distributing products in 40+ countries.
Is Mundipharma a public or private company?
Mundipharma is a private company. It is classified as family owned and is currently operating.
When was Mundipharma founded?
Mundipharma was founded in 1992. It employs 1,001 to 5,000 people.
Where is Mundipharma based?
Mundipharma is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Mundipharma make money?
Two revenue lines are on record. Prescription Pharmaceutical Products are the primary driver. The others are defenCath.
Who are Mundipharma's main competitors?
Direct peers on record are Mallinckrodt, Purdue Pharma, Grünenthal and Endo International. Cidara Therapeutics is listed as an emerging player. Hikma Pharmaceuticals is listed as a regional player. Broad incumbents are Stada Arzneimittel, Viatris, Astellas Pharma and GSK (GlaxoSmithKline).
Does Mundipharma have an API?
No public API is recorded for Mundipharma.
What industry is Mundipharma in?
Mundipharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.